Ascentage Pharma receives FDA green light for next-gen BTK degrader trial

Ascentage Pharma (NASDAQ:AAPG) shares were in focus on Tuesday, January 6, 2026, following the announcement that the U.S. FDA has cleared its Investigational New Drug (IND) application for APG-3288.

The clearance paves the way for a global, multicenter Phase I study evaluating this novel protein degrader in patients with relapsed or refractory B-cell malignancies, including those who have failed previous lines of standard therapy.

APG-3288 is a next-generation PROTAC (Proteolysis-Targeting Chimera) designed to combat the growing clinical challenge of drug resistance.

While traditional BTK inhibitors (like ibrutinib) merely block the protein's activity, APG-3288 physically removes the protein by tagging it for destruction by the body’s own waste-disposal system (the proteasome).

Crucially, preclinical data shows APG-3288 is highly effective against mutant BTK proteins (such as C481S and L528W) that render current blockbuster drugs ineffective.

The upcoming global Phase I trial will be an open-label study designed to determine the safety, tolerability, and optimal dosing of APG-3288.

Ascentage’s entry into the BTK degradation space places it in direct competition with emerging therapies from Beigene (BGB-16673) and Nurix Therapeutics (NX-2127), but the company claims its candidate offers superior potency and a more favorable pharmacokinetic profile.